Recruiting
Phase 1
Phase 2

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants with Advanced Solid Tumors

Sponsor:

Marengo Therapeutics, Inc.

Code:

NCT05592626

Conditions

Advanced Solid Tumors

Genital Neoplasm, Female

Urogenital Neoplasms

Lung Neoplasm

Neoplasms by Site

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

STAR0602

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information